Macquarie Group’s VYNE Therapeutics VYNE Stock Holding History

Macquarie Group’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-18	Closed	-$5K	–	2054
2018 Q4	$5K	Buy	+18	New	+$8.06K	﹤0.01%	2114

Other funds holding VYNE

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Macquarie Group's VYNE Position: Q1 2019 in Review

Macquarie Group sold out of VYNE Therapeutics (VYNE) in Q1 2019, closing a stake of 18 shares — an estimated $5K sold.

Macquarie Group first reported a position in VYNE in Q4 2018 and held it in 1 quarter. The position peaked at $5K in Q4 2018. 59 funds tracked by Wall St. Rank hold VYNE as of Q1 2019.

Macquarie Group reported no remaining VYNE Therapeutics position as of Q1 2019 after selling out during the quarter.
Macquarie Group sold 18 VYNE Therapeutics shares in Q1 2019, an estimated $5K.
Macquarie Group first reported a position in VYNE Therapeutics in Q4 2018 and held it in 1 quarter.
Macquarie Group's VYNE Therapeutics position peaked at $5K in Q4 2018.
59 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.